MELBOURNE, Australia,
Oct. 8, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of
68Ga-PSMA-11
[1] injection) to select patients for PSMA
[2]-targeted radionuclide therapy.
Register to read this story and more for free.
Signing up for an account helps us improve your browsing experience.
Continue
OR
See our subscription options.
Already have an account? Log in
here